Press Release

Geneos to Highlight Clinical and Supportive Pharmacodynamic Data From Personalized Therapeutic Cancer Vaccine Phase 1b/2a Clinical Trial at SITC Conference

–Encouraging Safety and Efficacy Data from Ongoing GT-30 Study in Second-Line HCC—


Plymouth Meeting, PA—October 13, 2022—Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that the company will release both clinical and supportive pharmacodynamic data from its ongoing GT-30 Phase 1b/2a clinical study of PTCV in second-line hepatocellular carcinoma (HCC) at the Society of Immunotherapy of Cancer (SITC) 37th Annual Meeting in November.


“We are pleased to have had four abstracts accepted by SITC and look forward to sharing the details of our clinical progress next month,” stated Dr. Niranjan Y. Sardesai, president and chief executive officer of Geneos. “We have been highly meticulous in designing every detail of our PTCVs, as well as in optimizing their administration for maximal immunologic activity, and are encouraged by the clinical results we are observing. We appreciate that SITC recognizes the importance of sharing these data in their peer-reviewed forum with our academic and industry colleagues in the field of immunotherapy.”


Details of Geneos Presentations at SITC Conference


  • Abstract #693: “Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab as second-line (2L) treatment for advanced hepatocellular carcinoma (HCC).” Oral presentation to be delivered by Edward Gane, MD, in Session 119 entitled “Vaccines: in Situ Agents and Novel Systemic Approaches” to be held from 6:05pm – 7:20pm on November 10th. Abstract #693 to be presented from 6:40pm – 6:50pm.


  • Abstract #691: “Immune pressure in an advanced hepatocellular cancer patient following treatment with personalized neoantigen DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab).” Poster presentation to be presented in Hall C by Mark Yarchoan, MD, between 9am and 9pm on November 10th.


  • Abstract #692: “Circulating tumor DNA analysis of advanced hepatocellular cancer (HCC) patients treated with neoantigen targeted personalized cancer DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab).” Poster presentation to be presented in Hall C by Jian Yan, PhD, between 9am and 9pm on November 11th.


  • Abstract #1174: “Multi-epitope DNA vaccine targeting cancer neoantigens enhances efficacy of anti-PD1 therapy.” Poster presentation to be presented in Hall C by Pratik Bhojnagarwala, MS, between 9am and 9pm on November 11th.


About Geneos Therapeutics
Geneos Therapeutics, a privately held, clinical stage biotherapeutics company, believes that personalized therapies will serve an important role in new treatment paradigms for cancer. The company is developing personalized therapeutic cancer vaccines (PTCV) to unleash the most powerful force against cancer – a patient’s own immune system. The company’s approach, using its proprietary GT-EPIC™ platform, is to target neoantigens (abnormal mutations produced by cancer cells) from individual patient tumors to develop novel and uniquely personalized treatments for cancer. Geneos has an experienced management team with a track record of success in building immunotherapy-based companies. For more information, please visit


Media Contact

Jennifer Williams

Cook Williams Communications, Inc.


* * *


This press release contains certain forward-looking statements relating to our business, including our plans regarding the development of personalized therapeutic cancer vaccines, our expectations regarding our research and development programs, including the planned expansion and conduct of clinical trials and the availability and timing of data from those trials, and the use of our capital resources. Actual events or results may differ from the expectations set forth herein. There can be no assurance that any product candidate in Geneos’ pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and Geneos undertakes no obligation to update or revise these statements, except as may be required by law.